About MalarVx
MalarVx is a company based in Seattle (United States) founded in 2012.. MalarVx has raised $1.05 million across 3 funding rounds from investors including HHS and Gamespools. The company has 5 employees as of December 31, 2022. MalarVx offers products and services including Malaria Vaccine. MalarVx operates in a competitive market with competitors including Altimmune, Biological E, Jaguar Health, Vaxart and Allergy Therapeutics, among others.
- Headquarter Seattle, United States
- Employees 5 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Malarvx Inc
-
Annual Revenue
$00as on Jun 21, 2017
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.05 M (USD)
in 3 rounds
-
Latest Funding Round
$447.45 K (USD), Grant
Sep 21, 2020
-
Investors
HHS
& 1 more
-
Employee Count
5
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MalarVx
MalarVx offers a comprehensive portfolio of products and services, including Malaria Vaccine. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops and tests vaccines to prevent malaria infections worldwide
Unlock access to complete
Unlock access to complete
Advisor Team
5 people
Leadership Team
2 people
Legal and Compliance
1 people
Product Management Team
1 people
Unlock access to complete
Funding Insights of MalarVx
MalarVx has successfully raised a total of $1.05M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $447.45 thousand completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $447,450
-
First Round
First Round
(01 Oct 2013)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Grant - MalarVx | Valuation |
investors |
|
| Jun, 2017 | Amount | Seed - MalarVx | Valuation |
investors |
|
| Oct, 2013 | Amount | Grant - MalarVx | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MalarVx
MalarVx has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Gamespools. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Gamespools is recognized as an online slot gaming platform.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MalarVx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - MalarVx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Malarvx Comparisons
Competitors of MalarVx
MalarVx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Altimmune, Biological E, Jaguar Health, Vaxart and Allergy Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Novel gastrointestinal products for humans and animals are developed sustainably.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for treating multiple infectious diseases
|
|
| domain | founded_year | HQ Location |
Aluminum-free allergy vaccines and diagnostics are developed for treatment.
|
|
| domain | founded_year | HQ Location |
Developer of vaccines for the treatment of infectious diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about MalarVx
When was MalarVx founded?
MalarVx was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Where is MalarVx located?
MalarVx is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is MalarVx a funded company?
MalarVx is a funded company, having raised a total of $1.05M across 3 funding rounds to date. The company's 1st funding round was a Grant of $249.28K, raised on Oct 01, 2013.
How many employees does MalarVx have?
As of Dec 31, 2022, the latest employee count at MalarVx is 5.
What does MalarVx do?
MalarVx is focussed on developing vaccines for malaria. It is working on the development of in vitro culture systems for the malaria parasite which will lead to the development of an effective whole-parasite vaccine. Its research showed that its lead candidate vaccine which is a genetically-attenuated P. falciparum parasite (GAP) has the potential to be effective without the use of adjuvants, immune boosters that have potential side-effects. The candidate is currently in phase 1 trials. It is also working with the Kappe lab to optimize the storage conditions for transporting a whole-parasite vaccine.
Who are the top competitors of MalarVx?
MalarVx's top competitors include Biological E, Jaguar Health and Vaxart.
What products or services does MalarVx offer?
MalarVx offers Malaria Vaccine.
Who are MalarVx's investors?
MalarVx has 2 investors. Key investors include HHS, and Gamespools.